A novel HSP90 inhibitor-drug conjugate to SN38 is highly effective in small cell lung cancer (SCLC)

PURPOSE: Small cell lung cancer (SCLC) is a highly aggressive disease representing 12-13% of total lung cancers, with median survival <2 years. No targeted therapies have proven effective in SCLC. While most patients respond initially to cytotoxic chemotherapies, resistance rapidly emerges, respo...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Clin Cancer Res
Main Authors: Gaponova, Anna V., Nikonova, Anna S., Deneka, Alexander, Kopp, Meghan C., Kudinov, Alexander E., Skobeleva, Natalia, Khazak, Vladimir, Ogawa, Luisa S., Cai, Kathy Q., Duncan, Kelly E., Duncan, James S., Egleston, Brian L., Proia, David A., Boumber, Yanis, Golemis, Erica A.
Format: Artigo
Jezik:Inglês
Izdano: 2016
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5065742/
https://ncbi.nlm.nih.gov/pubmed/27267850
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-3068
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki